Inhaled insulin: benefits in types 1 and 2 diabetes

'Exubera', an inhaled dry-powder insulin, is effective in the treatment of type 1 and type 2 diabetes mellitus, according to results from phase III studies presented at the 38th Annual Meeting of the European Association for the Study of Diabetes (EASD) [Budapest, Hungary; August-September 2002]. 'Exubera' was at least as effective as conventional SC insulin therapy in the treatment of type 1 and type 2 diabetes, and provided improved glycaemic control in patients with type 2 diabetes who had an insufficient response to oral antihyperglycaemic agents. An analysis of patients enrolled in phase II studies, showed that the level of satisfaction was greater in patients treated with 'Exubera', compared with those receiving conventional insulin therapy.